Nektar Therapeutics | NKTR - Cost Of Sales


Nektar Therapeutics reported $4.43M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 26.32B 2.79B Mar/2026
Dr.Reddys Laboratories INR 37.7B 1.54B Mar/2026
Eisai JPY 52.02B 931M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Exelixis USD 19.95M 6.53M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Xencor USD 61.66M 50.95M Jun/2025